학술논문
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study
Document Type
Article
Author
Sridhar, S.; Joaquin, A.; Bonaparte, M.I.; Chen, A.; Fu, B.; Janosczyk, H.; Meng, Y.; Romanyak, N.; von Barbier, D.; de Bruyn, G.; Canter, R.; Lopez, D.; Masotti, R.; Diazgranados, C.A.; Savarino, S.; Bueso, A.; Chabanon, A.-L.; Grillet, M.-H.; Chicz, R.M.; Diemert, D.; Essink, B.J.; Grunenberg, N.A.; Ramirez, S.; Keefer, M.C.; Munsiff, S.S.; Rivera M, D.M.; Michael, N.L.; Ogbuagu, O.; Raabe, V.N.; Severance, R.; Rivas, E.; Rouphael, N.G.; Schuerman, L.; Koutsoukos, M.; Ceregido, M.A.; Tavares-Da-Silva, F.; Sher, L.D.; Walsh, S.R.; White, J.; Keshtkar-Jahromi, M.; Mendoza, S.; Moreau, C.; Said, A.; Shi, J.; Tong, T.; Treanor, J.
Source
In: The Lancet Infectious Diseases . (The Lancet Infectious Diseases, May 2022, 22(5):636-648)
Subject
Language
English
ISSN
14744457
14733099
14733099